Field & Main Bank Makes New Investment in Abbott Laboratories $ABT

Field & Main Bank purchased a new stake in Abbott Laboratories (NYSE:ABT) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 7,180 shares of the healthcare product maker’s stock, valued at approximately $652,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. MidAtlantic Capital Management Inc. bought a new position in Abbott Laboratories in the 4th quarter worth approximately $25,000. Cornerstone Financial Management LLC bought a new stake in Abbott Laboratories during the 4th quarter valued at $25,000. Purpose Unlimited Inc. acquired a new position in Abbott Laboratories during the 4th quarter worth $25,000. Portfolio Resources Advisor Group Inc. bought a new position in shares of Abbott Laboratories in the fourth quarter worth $26,000. Finally, Abound Financial LLC bought a new position in shares of Abbott Laboratories in the fourth quarter worth $26,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott shares outperformed the broader market in the latest session, suggesting continued investor support for the diversified healthcare-products company. The move adds to its gains above both its 50-day and 200-day moving averages. Abbott Exceeds Market Returns: Some Facts to Consider
• Neutral Sentiment: A separate market comparison reported that Abbott underperformed its competitors during Tuesday’s trading session. The article did not identify a company-specific operational problem, making the relative weakness more relevant to short-term sentiment than to Abbott’s long-term fundamentals. Abbott Laboratories Stock Underperforms Tuesday
• Neutral Sentiment: Vice President John McCoy Jr. sold 27 shares for approximately $2,958. The transaction reduced his direct holdings by only 0.11%, leaving him with 24,549 shares, so it is too small to represent a meaningful change in insider conviction. SEC Insider Transaction Filing
• Neutral Sentiment: An investor-focused healthcare article mentioned Abbott primarily as the former parent of AbbVie, rather than discussing new developments at ABT. It therefore provides little direct information about Abbott’s near-term earnings or valuation. Abbott Laboratories Company Information

Abbott Laboratories Trading Down 1.5%

Shares of ABT stock opened at $108.81 on Friday. The stock has a 50-day simple moving average of $104.14 and a 200 day simple moving average of $100.06. The stock has a market capitalization of $188.28 billion, a P/E ratio of 35.21, a P/E/G ratio of 2.05 and a beta of 0.59. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the previous year, the business earned $1.26 earnings per share. Abbott Laboratories’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is 81.55%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Weiss Ratings upgraded shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 6th. The Goldman Sachs Group decreased their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. UBS Group dropped their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. BTIG Research upped their price target on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Finally, TD Cowen increased their price objective on shares of Abbott Laboratories from $115.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, August 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $119.50.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.